News | 30 May 2012
(Reuters) - Biotechnology company Alkermes Plc said it would stop development of its experimental drug to treat opioid-induced constipation after it failed to meet the main goal of a mid-stage study. The company said it would consider out-licensing the ...
Click on the link to read the full article at Reuters UK
(This link will open in a new window)